Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy

Melanoma of unknown primary (MUP) is considered different from melanoma of known primary (MKP), and it is unclear whether these patients benefit equally from novel therapies. In the current study, characteristics and overall survival (OS) of patients with advanced and metastatic MUP and MKP were com...

Descripción completa

Detalles Bibliográficos
Autores principales: Verver, Danielle, Grünhagen, Dirk J., van Akkooi, Alexander C. J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., van den Eertwegh, Alfonsus J. M., de Groot, Jan Willem B., Boers-Sonderen, Marye J., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., Tije, Albert J.ten, Vreugdenhil, Gerard, Verhoef, Cornelis, van der Veldt, Astrid A. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505371/
https://www.ncbi.nlm.nih.gov/pubmed/33774697
http://dx.doi.org/10.1007/s00262-021-02871-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505371/
https://www.ncbi.nlm.nih.gov/pubmed/33774697
http://dx.doi.org/10.1007/s00262-021-02871-1

Ejemplares similares